Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pneumococcal diseases

- PMLiVE

UK regulator warns of allergic reactions to Pfizer/BioNTech vaccine

New MHRA guidance comes after reports of allergic reactions to COVID-19 vaccine

- PMLiVE

NIAID chief back-pedals on criticism of UK’s Pfizer vaccine approval process

Anthony Fauci apologised for previous comments in BBC interview

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine gets first approval from UK

The UK has already signed a supply deal for 40 million doses

- PMLiVE

UK could approve Pfizer’s COVID-19 vaccine this week

The Telegraph reported the possible timeframe on Sunday

- PMLiVE

MSD launches antibiotic combo Recarbrio in UK

Therapeutic indicated to treat infections caused by Gram-negative bacteria

AstraZeneca AZ

AZ confirms the UK’s MHRA has started rolling review of its COVID-19 vaccine

Regulatory agency will review data as and when it becomes available

- PMLiVE

UK’s MHRA begins rolling review of Moderna’s coronavirus vaccine

MHRA will accept and consider new evidence as it becomes available

AstraZeneca AZ

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

PARP inhibitor now available for rare, life-threatening disease

- PMLiVE

Keytruda hits primary endpoint in confirmatory lymphoma trial

Interim analysis demonstrates improvement in progression-free survival

- PMLiVE

Merck’s Ebola vaccine wins approval in four African countries

Follows approvals in US and Europe last year

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

Merck spins off low-growth drugs in a ‘purposeful shift’ of focus

Fourth quarter results overshadowed by spin off announcement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links